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Introduction
Since the introduction of systemic chemotherapy in 1956 [1], 
gestational trophoblastic neoplasia (GTN) has evolved into one 
of the most curable gynecologic malignancies. This has oc-
curred primarily through sensitive assays for human chorionic 
gonadotrophin (hCG), advances in effective chemotherapy 
regimens, and the identification of risk factors that allow the 
individualization of chemotherapeutic treatment.
Although surgery has assumed a lesser role in the manage-
ment of women with malignant gestational trophoblastic 
disease, selected surgical procedures remain important to 
treatment [2]. Surgical intervention may be required for che-
moresistant disease in the uterus or at metastatic sites, and for 
life-threatening complications such as hemorrhage, bowel or 
urinary obstruction, or infection [3-5].
Patients with nonmetastatic or low-risk metastatic disease 
can be treated with single-agent chemotherapy [2]. However, 
patients with high-risk GTN require multiagent chemotherapy, 
with additional surgery or radiation.
Role of surgical therapy in the management of gestational 
trophoblastic neoplasia
Kyung Jin Eoh, Young Shin Chung, Ga Won Yim, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim
Women’s Cancer Clinic, Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, 
Seoul, Korea
Objective
To evaluate the role of adjuvant surgical procedures in the management of gestational trophoblastic neoplasia (GTN).
Methods
In a retrospective review of medical records at the Severance Hospital, we identified 174 patients diagnosed with GTN 
between 1986 and 2006. Of the 174 patients, 129 (74%) were assigned to the nonmetastatic group, and 45 (26%) to the 
metastatic group; of the metastatic group patients, 6 were in the low-risk group and 39 were in the high-risk group. Thirty-
two patients underwent 35 surgical procedures as part of the GTN treatment. The procedures included hysterectomy, 
lung resection, craniotomy, uterine wedge resection, uterine suturing for bleeding, salpingo-oophorectomy, pretherapy 
dilatation and curettage, adrenalectomy, nephrectomy, and uterine artery embolization.
Results
Of the 32 patients who underwent surgical procedures, 28 (87%) survived. Eleven patients underwent surgery for 
chemoresistant disease after receiving one or more chemotherapy regimens. Twelve patients underwent procedures 
to control tumor hemorrhage. Nine (81%) of 11 patients with chemoresistant disease survived, and 8 patients who 
underwent salvage surgery for chemoresistant disease received further chemotherapy. Of 21 patients who underwent 
hysterectomy, 19 (90%) achieved remission. All of three patients who had resistant foci of choriocarcinoma in the lung 
achieved remission through pulmonary resection.
Conclusion
Adjuvant surgical procedures, especially hysterectomy and pulmonary resection for chemoresistant disease, as well as 
procedures to control hemorrhage, are pivotal in the management of GTN.
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The objective of this study was to evaluate the role of adju-
vant surgical procedures in the management of GTN.
Materials and methods 
Between 1986 and 2006, 174 patients diagnosed with GTN 
were treated with chemotherapy at Severance Hospital. Pa-
tients were grouped according to the International Federation 
of Gynecology and Obstetrics (FIGO) stage and risk score. A 
FIGO risk score of ≥7 or the presence of one or more risk fac-
tors according to the clinical classification system was indica-
tive of high-risk disease. Of the 174 patients, 129 (74%) were 
assigned to the nonmetastatic group; and 45 (26%), to the 
metastatic group. In the metastatic group, six patients were in 
the low-risk group and 39 were in the high-risk group. From 
this patient population, we identified 32 patients who under-
went 35 surgical procedures as part of GTN treatment. The 
procedures included hysterectomy, pulmonary resection, cra-
niotomy, uterine wedge resection, uterine suturing, salpingo-
oophorectomy, pretherapy dilatation and curettage, adrenal-
ectomy, nephrectomy, and uterine artery embolization.
Chemoresistant disease was defined as a plateau or increase 
in the level of hCG when the patient had achieved either a 
partial response (>50% decrease in hCG titers compared with 
the value at therapy initiation) or no response (≤50% decrease 
in hCG titers compared with the value at therapy initiation).
Results
Complete remission was achieved in all patients with non-
metastatic and low-risk metastatic diseases and in 31 (79%) 
of the 39 patients with high-risk metastatic disease. However, 
8 patients died.
In 32 patients, 35 surgical procedures were performed. Two 
patients underwent more than one surgical procedure, includ-
ing hysterectomy, adrenalectomy, craniotomy, hysterectomy, 
and uterine artery embolization. The presurgery characteris-
tics of the 32 patients are presented in Table 1. The median 
age of the patients at presentation was 36 years (range, 22 
to 56 years). Thirteen patients had a pretreatment hCG level 
of ≥40,000 mIU/mL. Thirteen patients had an interval of ≥4 
months from the antecedent pregnancy to treatment, 16 had 
an antecedent nonmolar pregnancy, and five had brain me-
tastases. FIGO stage was I in 14, II in one, III in 12, and IV in 
five patients. In the metastatic group, two women were in the 
low-risk group and 15 were in the high-risk group. The FIGO 
prognostic risk factor scores ranged from 3 to 20 (median, 8.7). 
Twenty-one patients had risk scores ≥7. Pathology reports of 
surgical specimens identified 19 cases of choriocarcinoma, 
nine cases of invasive mole, two cases of hydatidiform mole, 
and two cases with nonviable trophoblast.
Table 1. Patient characteristics (n=32)
Characteristics No. of patients (%)
Antecedent pregnancy
Hydatidiform mole 16 (50)
Abortion 10 (31)
Full-term 6 (19)
Initial FIGO stage
1 14 (44)
2 1 (3)
3 12 (38)
4 5 (15)
Preoperative chemotherapy
Yes 20 (63)
No 12 (37)
No. of preoperative chemotherapy regimens
1 7 (35)
2 9 (45)
3 1 (5)
≥4 3 (15)
Type of preoperative chemotherapy regimens (n=45)
MAC 5
EMA-CO 9
Platinum-based 9
Other, methotrexate-based 16
Other, nonmetastatic-based 6
Preoperative hCG level (mIU/mL)
Median 96,477
Range 58–800,000
FIGO risk scoring
<7 10 (31)
≥7 22 (69)
FIGO, International Federation of Gynecology and Obstetrics; MAC, 
methotrexate, actinomycin-D, and cyclophosphamide; EMA-CO, etopo-
side, methotrexate, actinomycin-D, and cyclophosphamide, and vincris-
tine; hCG, human chorionic gonadotrophin.
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Twenty patients received preoperative chemotherapy. Be-
fore surgery, 45 different chemotherapy regimens were ad-
ministered, including methotrexate, dactinomycin, and cyclo-
phosphamide or chlorambucil regimens in 5 cases; etoposide, 
methotrexate, dactinomycin, cyclophosphamide, and vincris-
tine regimens in 9 cases; platinum-based regimens in 9 cases; 
miscellaneous methotrexate-based regimens in 16 cases; and 
miscellaneous non-methotrexate-based regimens in 6 cases 
(Table 1).
The surgical procedures and their indications are listed in 
Table 2. Total abdominal hysterectomy was performed in 21 
patients, lung wedge resection in 3 patients, and craniotomy 
in 4 patients. In selected patients, hysterectomy decreased the 
likelihood of postmolar GTN (Fig. 1). Moreover, procedures 
such as uterine wedge resection, salpingo-oophorectomy, pre-
therapy dilatation and curettage, uterine suturing, adrenalec-
tomy, nephrectomy, and uterine artery embolization were all 
performed once. After one or more chemotherapy regimens, 
11 (34%) of 32 patients underwent surgery for chemoresis-
tant disease. Of the 32 patients, 12 (38%) underwent proce-
dures to control tumor hemorrhage. Five patients underwent 
procedures as adjuvant therapy at the start of chemotherapy. 
In addition, two patients underwent operations due to toxicity 
of chemotherapy.
Of the 32 patients, 28 (87%) who underwent surgical pro-
cedures survived. Four patients died, of whom one had stage 
III and three had stage IV disease, with FIGO scores of 12, 20, 
14, and 10. Of the four patients who died, one died approxi-
mately 15 months after hysterectomy for chemoresistant cho-
riocarcinoma. She had FIGO stage IV disease with brain, liver, 
kidney, lung, skin, and adrenal gland metastases. Left adre-
nalectomy was also performed for resection of resistant foci. 
Thereafter, she underwent craniotomy with tumor resection 
and removal of hematoma from acute hemorrhage, and ste-
reotactic radiosurgery was performed after surgery. Another 
patient who experienced an intracerebral hemorrhage during 
chemotherapy underwent emergent craniotomy followed by 
postoperative chemotherapy and gamma knife irradiation, 
but eventually died of persistent disease. One patient had 
FIGO stage IV disease with brain and kidney metastases, and 
presented with hemoperitoneum. The patient was diagnosed 
with renal hemorrhage. Right nephrectomy was performed 
to control tumor hemorrhage. Afterward, the patient died of 
intracerebral hemorrhage while on ventilator support in the 
intensive care unit. The fourth patient died of chemoresistant 
disease, approximately 11 months after hysterectomy. She 
had undergone gastrectomy for stomach cancer; after hyster-
ectomy, the pulmonary lesion aggravated, with the disease 
progressing despite postoperative chemotherapy.
Of 21 patients, 19 (90%) who underwent hysterectomy sur-
vived. All three patients who had resistant foci of choriocarci-
noma in the lung achieved remission after pulmonary resection.
Five patients had brain metastases, all of whom also had pul-
monary metastases. Craniotomy was performed in 4 patients. 
Emergent craniotomy with tumor resection and hematoma 
removal were performed for acute intracerebral hemorrhage. 
Table 2. Adjuvant surgical procedures and indication of surgery
No.
Adjuvant surgical procedures
Hysterectomy 21
Lung wedge resection 3
Craniotomy 4
Uterine wedge resection 1
Salpingooophorectomy 1
Pretherapy dilatation and curettage 1
Suturing of uterus 1
Adrenalectomy 1
Nephrectomy 1
Uterine artery embolization 1
Indication of surgery
Salvage surgery for chemoresistant disease 13
Control tumor hemorrhage 13
Primary adjuvant 7
Others 2
Fig. 1. A 16-week uterus filled with complete hydatidiform moles.
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In three patients, postoperative multiagent chemotherapy 
was administered for choriocarcinoma diagnosed on surgical 
pathological examination. One patient received whole-brain 
radiation, and two patients underwent stereotactic radiosur-
gery after surgery. Complete remissions were achieved in two 
patients. Three of five patients with brain metastases died.
Table 3 shows the details of 11 patients who underwent 
surgery for chemoresistant disease after receiving one or more 
chemotherapy regimens. All patients had high-risk diseases. 
Of the 11 patients, 9 (81%) survived. Eight patients received 
further chemotherapy after surgical procedures. The median 
interval from diagnosis to surgery was 12 months. Of the 
seven women who underwent hysterectomies for resistant 
disease, three had nonmetastatic disease, three had lung 
metastasis, and one had multiple metastases, including the 
brain, liver, kidney, lung, skin, and adrenal gland. Of the seven 
patients, 5 (71%) also perioperatively received chemotherapy, 
five had complete remission, and two died of recurrent or 
persistent disease.
Pulmonary resection for removal of resistant foci of cho-
riocarcinoma in the lung was performed in 3 patients, all of 
whom had complete disease remission after the operations. 
Uterine wedge resection was performed in one patient.
A pathological diagnosis of choriocarcinoma was made after 
salvage surgeries in 7 cases, and one case each of hydatidi-
form and invasive moles were also identified. Pathologically 
negative findings were obtained for two patients.
Discussion
Approximately half to two-third of patients with high-risk 
GTN need surgery during the course of therapy to remove 
disease or treat complications [6-8]. Lewis et al. [9] reported 
that the most common surgery was for hemorrhage control. 
With improvement in technology and development of other 
effective chemotherapeutic agents, the indications for surgery 
have changed. Currently, the most common surgical approach 
appears to be resection of chemoresistant foci of disease. In 
our series, surgery was most commonly performed for hem-
orrhage control in 12 cases, followed by salvage surgery for 
chemoresistant disease, which was performed in 11 patients.
Hammond et al. [3] reported that patients with nonmeta-
static or low-risk metastatic gestational trophoblastic disease 
who were treated with primary hysterectomy with chemo-
therapy had a shorter duration and lower total dosage of 
chemotherapy than patients who were treated with chemo-
therapy alone. Primary hysterectomy may be considered in se-
lected patients with high-risk metastatic GTN with evidence of 
uterine disease. Delayed hysterectomy is often considered for 
patients who fail to respond to primary chemotherapy. In our 
study, 6 primary adjuvant hysterectomies were all performed 
for nonmetastatic disease, and the mean age of the patients 
was 47 years, which means that fertility preservation was not 
required. Five (71%) of 7 patients who underwent salvage 
hysterectomy for chemoresistant disease had complete clinical 
response to surgery.
Resection of pulmonary nodules in highly selected patients 
with drug-resistant disease may also be successful in inducing 
remission [4,10-17]. Before performing pulmonary resection, 
it is important to rule out other concomitant diseases through 
extensive preoperative imaging. Tomoda et al. [16] reported 
that 14 (93%) of their 15 patients with isolated, unilateral 
nodules associated with low urinary hCG values benefited 
from thoracotomy with pulmonary resection. Xu et al. [18] 
noted improved survival in patients who had a solitary lung le-
sion without metastases to other organs and a good response 
to chemotherapy. In our study, all the three patients who met 
the above-mentioned criteria established by Tomoda et al. [16] 
underwent pulmonary resection for chemoresistant disease 
and achieved complete remission.
Brain metastases of GTN tend to be highly vascular and 
develop central necrosis and hemorrhage. Thus, patients with 
brain metastases are at risk of early intracerebral hemorrhage, 
neurological deterioration, and early death. A combination 
of multiagent and whole-brain radiation therapies, treatment 
with early neurosurgical intervention or stereotactic radio-
surgery, and combination chemotherapy with methotrexate 
systemic and intrathecal regimens have been reported to have 
similar cure rates as high as 75% [19-22]. Treatment with 
the combination of chemotherapy and whole-brain radiation 
therapy may be associated with late neurotoxicity such as 
impaired cognitive function. dementia, gait ataxia, and be-
havioral changes. Stereotactic radiation therapy allows precise 
delivery of a single high-dose fraction of radiation to a small 
target volume, with a sharp fall-off of the dose to adjacent 
normal tissues [20]. In our study, four patients received emer-
gent craniotomy with hematoma removal and tumor resec-
tion for acute cerebral hemorrhage, followed by postoperative 
chemotherapy and whole-brain irradiation in one and gamma 
knife irradiation in the other two patients. Two of the five 
patients with brain metastases survived without neurological 
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sequelae. An interesting finding in our series concerns the use 
of postoperative chemotherapy. The patients who received 
chemotherapy within 1 week of craniotomy seemed to be 
less likely to have a recurrence than those who received che-
motherapy more than 1 week after surgery. Thus, timing of 
perioperative chemotherapy may play a role in preventing late 
metastatic disease.
Selective angiographic embolization of the uterine arteries, 
instead of surgical intervention, may also be used to control 
uterine or pelvic tumor bleeding. In one case, after hydatidi-
form mole was diagnosed, hysterectomy was performed at 
first. Two years later, uterine artery embolization had to be 
performed because of active vaginal bleeding from the vaginal 
metastasis of the choriocarcinoma. Postoperative chemothera-
py led to complete remission.
The limitation of this study is its retrospective nature. Selec-
tion bias might have been introduced because the surgical 
method was not randomized but determined by the surgeon. 
However, there were no drastic alterations of adjuvant surgi-
cal procedures, which may affect surgical outcomes in the 
management of GTN. One of the strengths of this study is 
the relatively large number of study subjects with GTN who 
received surgical treatment with consistency in its precision.
We conclude that adjuvant surgical procedures, especially 
hysterectomy and pulmonary resection for chemotherapy-
resistant disease, as well as procedures to control hemorrhage, 
are pivotal in the management of GTN.
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